---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-184757"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2023-07-10T23:59:59+00:00"
generated_at: "2026-06-13T10:35:14.014363+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Viridian announces positive Phase 1/2 data for VRDN-001 in chronic TED; THRIVE trial amended

## Summary
- VRDN-001 showed mean proptosis reduction of 1.6 mm (combined doses) at week 6; proptosis responder rate 42%.
- No serious adverse events, hearing impairment, or hyperglycemia reported in chronic TED patients.
- THRIVE Phase 3 trial amended to 5-dose regimen; topline results expected mid-2024.
- THRIVE-2 Phase 3 in chronic TED to start Q3 2023; topline results expected by year-end 2024.
- IND filed for VRDN-003 and VRDN-001 SC; lead SC candidate selection expected by year-end 2023.

## SEC filing metadata
- accession: 0001193125-23-184757
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2023-07-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312523184757/0001193125-23-184757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312523184757/d440197d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-184757
- JSON: https://secwatch.observer/filing/0001193125-23-184757.json
- Plain text: https://secwatch.observer/filing/0001193125-23-184757.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.